{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:20:03Z","timestamp":1787768403233,"version":"build-2784847793"},"reference-count":22,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"GlaxoSmithKline"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2715900","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:43:57Z","timestamp":1787766237000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1276-5250","authenticated-orcid":false,"given":"Robynne","family":"Wong","sequence":"first","affiliation":[{"name":"GSK","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Kuznetsova","sequence":"additional","affiliation":[{"name":"GSK","place":["Wavre, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emna","family":"Baba","sequence":"additional","affiliation":[{"name":"GSK","place":["Wavre, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9116-3117","authenticated-orcid":false,"given":"Tapiwa","family":"Ganyani","sequence":"additional","affiliation":[{"name":"GSK","place":["Wavre, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8427-759X","authenticated-orcid":false,"given":"Stefano","family":"Berr\u00e8","sequence":"additional","affiliation":[{"name":"GSK","place":["Rixensart, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Boutet","sequence":"additional","affiliation":[{"name":"GSK","place":["Rixensart, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Ramanathan","sequence":"additional","affiliation":[{"name":"GSK","place":["Rockville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Douglas","sequence":"additional","affiliation":[{"name":"Paratus Clinical","place":["Chatswood, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-2032","authenticated-orcid":false,"given":"Philipp","family":"Mann","sequence":"additional","affiliation":[{"name":"CureVac SE","place":["Wiesbaden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3743-5281","authenticated-orcid":false,"given":"Martin Robert","family":"Gaudinski","sequence":"additional","affiliation":[{"name":"GSK","place":["Rockville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"e_1_3_5_2_1","first-page":"1989","article-title":"Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950\u20132021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the global burden of disease study 2021","volume":"403","author":"GBD Demographics collaborators","year":"2021","unstructured":"GBD Demographics collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950\u20132021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the global burden of disease study 2021. Lancet 2024. 2021;403:1989\u201315.","journal-title":"Lancet 2024"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081320"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.02.016"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01426-23"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00217-5"},{"key":"e_1_3_5_7_1","unstructured":"World Health Organization. WHO COVID-19 dashboard. 2025 [accessed 2025 Sep 10]. https:\/\/data.who.int\/dashboards\/covid19\/deaths."},{"key":"e_1_3_5_8_1","first-page":"e943911","article-title":"Editorial: global Health concerns as vaccine-preventable infections including SARS-CoV-2 (JN.1), influenza, respiratory syncytial virus (RSV), and measles continue to rise","volume":"30","author":"Parums DV","year":"2024","unstructured":"Parums DV. Editorial: global Health concerns as vaccine-preventable infections including SARS-CoV-2 (JN.1), influenza, respiratory syncytial virus (RSV), and measles continue to rise. Med Sci Monit. 2024;30:e943911.","journal-title":"Med Sci Monit"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01080-4"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsestwater.3c00032"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29462"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/envhealth.5c00048"},{"key":"e_1_3_5_13_1","unstructured":"World Health Organization. COVID-19 advice for the public: getting vaccinated. 2024 [accessed 2025 Oct 28]. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00841-7"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898192"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00283-5"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2408863"},{"key":"e_1_3_5_18_1","unstructured":"Weir JP. Considerations and recommendations for the 2025\u20132026 formula of COVID-19 vaccines in the United States. 2025 [accessed 2026 May 6]. https:\/\/www.fda.gov\/media\/186594\/download."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-021-00536-y"},{"key":"e_1_3_5_20_1","unstructured":"Comirnaty (COVID-19 vaccine mRNA). Package insert. Pfizer. 2025 [accessed 2026 Jan 12]. https:\/\/www.fda.gov\/media\/151707\/download."},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae081"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.08.011"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1501275"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2715900","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/21645515.2026.2715900","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2715900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:43:59Z","timestamp":1787766239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2715900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2715900"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2715900","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2715900"}}